

Julie K Schwarz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8333657/publications.pdf>

Version: 2024-02-01

81
papers

4,174
citations

126907

33
h-index

114465

63
g-index

83
all docs

83
docs citations

83
times ranked

5780
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase I Trial of Stereotactic MRI-Guided Online Adaptive Radiation Therapy (SMART) for the Treatment of Oligometastatic Ovarian Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 379-389.	0.8	28
2	SERPINB3 (SCCA1) inhibits cathepsin L and lysoptosis, protecting cervical cancer cells from chemoradiation. <i>Communications Biology</i> , 2022, 5, 46.	4.4	10
3	The impact of tumor size and histology on local control when utilizing high-dose-rate interstitial brachytherapy for gynecologic malignancies. <i>Gynecologic Oncology</i> , 2022, , .	1.4	0
4	Localized Delivery of Cisplatin to Cervical Cancer Improves Its Therapeutic Efficacy and Minimizes Its Side Effect Profile. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1483-1494.	0.8	37
5	Integrating imaging and RNA-seq improves outcome prediction in cervical cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	14
6	Standardized Uptake Value for 18F-Fluorodeoxyglucose Is a Marker of Inflammatory State and Immune Infiltrate in Cervical Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4245-4255.	7.0	15
7	In Regard to Salama etÂal. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 918-919.	0.8	0
8	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. <i>Nature Communications</i> , 2021, 12, 5086.	12.8	58
9	Genomic Characterization and Therapeutic Targeting of HPV Undetected Cervical Carcinomas. <i>Cancers</i> , 2021, 13, 4551.	3.7	13
10	Cardiac radiotherapy induces electrical conduction reprogramming in the absence of transmural fibrosis. <i>Nature Communications</i> , 2021, 12, 5558.	12.8	75
11	Alteration of Cellular Reduction Potential Will Change 64Cu-ATSM Signal With or Without Hypoxia. <i>Journal of Nuclear Medicine</i> , 2020, 61, 427-432.	5.0	11
12	Decreased local immune response and retained HPV gene expression during chemoradiotherapy are associated with treatment resistance and death from cervical cancer. <i>International Journal of Cancer</i> , 2020, 146, 2047-2058.	5.1	26
13	Tumor Microenvironment as a Regulator of Radiation Therapy: New Insights into Stromal-Mediated Radioresistance. <i>Cancers</i> , 2020, 12, 2916.	3.7	63
14	Targeting Tumor Metabolism to Overcome Radioresistance. <i>Cancer Drug Discovery and Development</i> , 2020, , 219-263.	0.4	2
15	Glutaminase Inhibitors Induce Thiol-Mediated Oxidative Stress and Radiosensitization in Treatment-Resistant Cervical Cancers. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2465-2475.	4.1	25
16	Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer. <i>Cancer</i> , 2020, 126, 4948-4956.	4.1	37
17	HPV-EM: an accurate HPV detection and genotyping EM algorithm. <i>Scientific Reports</i> , 2020, 10, 14340.	3.3	3
18	Long-term outcomes of intensity-modulated radiation therapy (IMRT) and high dose rate brachytherapy as adjuvant therapy after radical hysterectomy for cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1157-1161.	2.5	10

#	ARTICLE	IF	CITATIONS
19	Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer. <i>Cancer Cell</i> , 2020, 37, 289-307.e9.	16.8	252
20	Early posttherapy clearance of human papillomavirus and treatment response in cervical carcinoma. <i>Cancer</i> , 2020, 126, 4168-4176.	4.1	2
21	Therapy-Induced Senescence Drives Bone Loss. <i>Cancer Research</i> , 2020, 80, 1171-1182.	0.9	69
22	FIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival. <i>Gynecologic Oncology</i> , 2020, 157, 639-643.	1.4	57
23	Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	148
24	Neutrophils promote tumor resistance to radiation therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 18584-18589.	7.1	102
25	Intensity Modulated Radiation Therapy and Image-Guided Adapted Brachytherapy for Cervix Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 1088-1097.	0.8	57
26	Concurrent chemoradiation for cervical cancer: Comparison of LDR and HDR brachytherapy. <i>Brachytherapy</i> , 2019, 18, 353-360.	0.5	6
27	Clinical outcomes after isolated pelvic failure in cervical cancer patients treated with definitive radiation. <i>Gynecologic Oncology</i> , 2019, 153, 530-534.	1.4	10
28	MRI safety risks in the obese: The case of the disposable lighter stored in the pannus. <i>Radiology Case Reports</i> , 2019, 14, 634-638.	0.6	5
29	Impact of tumor histology on detection of pelvic and para-aortic nodal metastasis with ¹⁸ F-fluorodeoxyglucose-positron emission tomography in stage IB cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1351-1354.	2.5	8
30	Brachytherapy and survival in small cell cancer of the cervix and uterus. <i>Brachytherapy</i> , 2019, 18, 163-170.	0.5	16
31	Manipulation of Glucose and Hydroperoxide Metabolism to Improve Radiation Response. <i>Seminars in Radiation Oncology</i> , 2019, 29, 33-41.	2.2	26
32	A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer. <i>Cancer Medicine</i> , 2019, 8, 437-446.	2.8	7
33	Radioresistant Cervical Cancers Are Sensitive to Inhibition of Glycolysis and Redox Metabolism. <i>Cancer Research</i> , 2018, 78, 1392-1403.	0.9	69
34	The Future of Radiobiology. <i>Journal of the National Cancer Institute</i> , 2018, 110, 329-340.	6.3	76
35	Multi-institutional Analysis of Vaginal Brachytherapy Alone for Women With Stage II Endometrial Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 1069-1077.	0.8	19
36	Survival of Cervical Cancer Patients Presenting with Occult Supraclavicular Metastases Detected by FDG-Positron Emission Tomography/CT: Impact of Disease Extent and Treatment. <i>Gynecologic and Obstetric Investigation</i> , 2018, 83, 83-89.	1.6	8

#	ARTICLE	IF	CITATIONS
37	Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer. <i>British Journal of Cancer</i> , 2018, 118, 72-78.	6.4	46
38	Spatial relationship of 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography and magnetic resonance diffusion imaging metrics in cervical cancer. <i>EJNMMI Research</i> , 2018, 8, 52.	2.5	11
39	(P23) Toxicity of Post-Operative Intensity Modulated Radiation Therapy in Patients With Endometrial Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, E30.	0.8	0
40	Clinical outcomes and differential effects of PI3K pathway mutation in obese versus non-obese patients with cervical cancer. <i>Oncotarget</i> , 2018, 9, 4061-4073.	1.8	14
41	Association of post-treatment positron emission tomography with locoregional control and survival after radiation therapy for squamous cell carcinoma of the vulva. <i>Radiotherapy and Oncology</i> , 2017, 122, 445-451.	0.6	12
42	Which patients with inoperable vulvar cancer may benefit from brachytherapy in addition to external beam radiation? A Surveillance, Epidemiology, and End Results analysis. <i>Brachytherapy</i> , 2017, 16, 831-840.	0.5	10
43	Intensity modulated radiation therapy for squamous cell carcinoma of the vulva: Treatment technique and outcomes. <i>Advances in Radiation Oncology</i> , 2017, 2, 148-158.	1.2	33
44	Patterns of care and outcomes of proton and eye plaque brachytherapy for uveal melanoma: Review of the National Cancer Database. <i>Brachytherapy</i> , 2017, 16, 1225-1231.	0.5	18
45	(P044) Toxicity of Post-Operative Intensity Modulated Radiation Therapy in Patients With Cervical Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, E27.	0.8	0
46	Improved survival with definitive chemoradiation compared to definitive radiation alone in squamous cell carcinoma of the vulva: A review of the National Cancer Database. <i>Gynecologic Oncology</i> , 2017, 146, 572-579.	1.4	34
47	Patterns of care and survival outcomes after treatment for uveal melanoma in the post-coms era (2004-2013): a surveillance, epidemiology, and end results analysis. <i>Journal of Contemporary Brachytherapy</i> , 2017, 5, 453-465.	0.9	27
48	An analysis of appropriate delivery of postoperative radiation therapy for endometrial cancer using the RAND/UCLA Appropriateness Method: Executive summary. <i>Advances in Radiation Oncology</i> , 2016, 1, 26-34.	1.2	8
49	Clinical implementation of multisequence MRI-based adaptive intracavitary brachytherapy for cervix cancer. <i>Journal of Applied Clinical Medical Physics</i> , 2016, 17, 121-131.	1.9	14
50	Intensity modulated radiation therapy for recurrent ovarian cancer refractory to chemotherapy. <i>Gynecologic Oncology</i> , 2016, 141, 134-139.	1.4	37
51	Medically inoperable endometrial cancer in patients with a high body mass index (BMI): Patterns of failure after 3-D image-based high dose rate (HDR) brachytherapy. <i>Radiotherapy and Oncology</i> , 2016, 118, 167-172.	0.6	32
52	PET/MRI Evaluation of Gynecologic Malignancies and Prostate Cancer. <i>Seminars in Nuclear Medicine</i> , 2015, 45, 293-303.	4.6	32
53	Outpatient-based high-dose-rate interstitial brachytherapy for gynecologic malignancies. <i>Brachytherapy</i> , 2015, 14, 231-237.	0.5	15
54	<i>BRAF</i> mutation is not predictive of long-term outcome in papillary thyroid carcinoma. <i>Cancer Medicine</i> , 2015, 4, 791-799.	2.8	58

#	ARTICLE	IF	CITATIONS
55	Brachytherapy Is Associated With Improved Survival in Inoperable Stage I Endometrial Adenocarcinoma: A Population-Based Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 649-657.	0.8	34
56	Consensus statement for brachytherapy for the treatment of medically inoperable endometrial cancer. <i>Brachytherapy</i> , 2015, 14, 587-599.	0.5	93
57	Adjuvant radiotherapy in Stage II endometrial carcinoma: Is brachytherapy alone sufficient for local control?. <i>Brachytherapy</i> , 2015, 14, 427-432.	0.5	19
58	Three-dimensional dose accumulation in pseudo-split-field IMRT and brachytherapy for locally advanced cervical cancer. <i>Brachytherapy</i> , 2015, 14, 481-489.	0.5	9
59	Intracavitary Brachytherapy for Gynecologic Malignancies: Applications and Innovations. <i>Missouri Medicine</i> , 2015, 112, 366-72.	0.3	2
60	AKT Inhibitors Promote Cell Death in Cervical Cancer through Disruption of mTOR Signaling and Glucose Uptake. <i>PLoS ONE</i> , 2014, 9, e92948.	2.5	68
61	Activation of miR-9 by human papillomavirus in cervical cancer. <i>Oncotarget</i> , 2014, 5, 11620-11630.	1.8	53
62	Cervical Gross Tumor Volume Dose Predicts Local Control Using Magnetic Resonance Imaging/Diffusion-Weighted Imaging-Guided High-Dose-Rate and Positron Emission Tomography/Computed Tomography-Guided Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 794-801.	0.8	52
63	Treatment Approach, Surveillance, and Outcome of Well-Differentiated Thyroid Cancer in Childhood and Adolescence. <i>Thyroid</i> , 2014, 24, 1121-1126.	4.5	79
64	In vitro chemoresponse to cisplatin and outcomes in cervical cancer. <i>Gynecologic Oncology</i> , 2013, 130, 188-191.	1.4	7
65	Translating Imaging Results into Tumor Biology: FDG-PET and The Response to Chemoradiation in Human Cervical Carcinoma. <i>Radiation Research</i> , 2013, 180, 223-230.	1.5	1
66	Tumor volume and subvolume concordance between FDG-PET/CT and diffusion-weighted MRI for squamous cell carcinoma of the cervix. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 37, 431-434.	3.4	44
67	Molecular Imaging of Very Late Antigen ⁴ ($\alpha_4\beta_1$ Integrin) in the Premetastatic Niche. <i>Journal of Nuclear Medicine</i> , 2012, 53, 779-786.	5.0	37
68	Metabolic Response on Post-therapy FDG-PET Predicts Patterns of Failure After Radiotherapy for Cervical Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 185-190.	0.8	82
69	Prognostic Significance of p16 Expression in Advanced Cervical Cancer Treated With Definitive Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 153-157.	0.8	28
70	Pathway-Specific Analysis of Gene Expression Data Identifies the PI3K/Akt Pathway as a Novel Therapeutic Target in Cervical Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 1464-1471.	7.0	90
71	Prospective Phase I-II Trial of Helical Tomotherapy With or Without Chemotherapy for Postoperative Cervical Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1258-1263.	0.8	15
72	A MicroRNA Expression Signature for Cervical Cancer Prognosis. <i>Cancer Research</i> , 2010, 70, 1441-1448.	0.9	294

#	ARTICLE	IF	CITATIONS
73	A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2009, 114, 457-464.	1.4	262
74	The Role of ¹⁸ F-FDG PET in Assessing Therapy Response in Cancer of the Cervix and Ovaries. <i>Journal of Nuclear Medicine</i> , 2009, 50, 64S-73S.	5.0	97
75	Tumor Response and Survival Predicted by Post-Therapy FDG-PET/CT in Anal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 180-186.	0.8	121
76	¹⁸ F-Fluorodeoxyglucoseâ€“Positron Emission Tomography Evaluation of Early Metabolic Response During Radiation Therapy for Cervical Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1502-1507.	0.8	53
77	False-Positive Rate of Posttherapy Positron Emission Tomography in Cervical Cancerâ€“Reply. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 898.	7.4	0
78	Association of Posttherapy Positron Emission Tomography With Tumor Response and Survival in Cervical Carcinoma. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 2289.	7.4	260
79	Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation. <i>Molecular Cancer Research</i> , 2003, 1, 598-609.	3.4	105
80	The Chk1 Protein Kinase and the Cdc25C Regulatory Pathways Are Targets of the Anticancer Agent UCN-01. <i>Journal of Biological Chemistry</i> , 2000, 275, 5600-5605.	3.4	464
81	Gradational Threat Postures by the Red-Backed Salamander. <i>Journal of Herpetology</i> , 1991, 25, 112.	0.5	38